Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06068075 · ClinicalTrials.gov registry record · NA
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
A NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 340
- Enrollment target
- 15
- Study locations
NCT06068075: Recruiting NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor, sponsored by Dana-Farber Cancer Institute.
NCT06068075 is a NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 340 participants, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (251% higher). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06068075, a NA study of Ewing Sarcoma and Peripheral Primitive Neuroectodermal Tumor, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
Primary Outcome
Proportion of patient without an event by baseline detection of ctDNA
Conditions Studied
Interventions
- OTHER FoundationOne Liquid CDx
Study Locations (15)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
California
- Childrens Hospital Los Angeles - Los Angeles
Georgia
- Children's Healthcare of Atlanta - Atlanta
Minnesota
- Children's Hospital's and Clinics of Minnesota - Minneapolis
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Rhode Island
- Lifespan / Rhode Island Hospital - Providence
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT06068075 shows while recruiting
NCT06068075 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, above the 97-participant average among 26 other Ewing Sarcoma trials with a reported enrollment target (251% higher).
The record links to 7 conditions, with Ewing Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which FoundationOne Liquid CDx is the first listed.
NCT06068075 lists 15 locations in 11 states (Massachusetts, Ohio, California).
Frequently Asked Questions
What is clinical trial NCT06068075 about?
NCT06068075 is a clinical study titled "Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD". This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
What is the current status of trial NCT06068075?
This trial is currently recruiting. It is a NA study. The enrollment target is 340 participants. The study started on 2018-05-08. Estimated completion is 2027-01-01.
What conditions does trial NCT06068075 study?
This clinical trial studies the following conditions: Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Ewing Sarcoma of Bone, High-grade Osteosarcoma, Ewing Sarcoma of Soft Tissue.
What interventions are being tested in trial NCT06068075?
The interventions under investigation include: FoundationOne Liquid CDx (OTHER).
Who is sponsoring clinical trial NCT06068075?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06068075 being conducted?
This trial has 15 study locations across California, Georgia, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ewing Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06068075's enrollment target sits among peer trials
340 2nd of 26 the highest of 26 other Ewing Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ewing Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
RECRUITING · NA
-
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI